Wakamoto Pharmaceutical Co., Ltd. (JP:4512)

:4512

4512

Wakamoto Pharmaceutical Co., Ltd.

RESEARCH TOOLSreports

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

Compare

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥270.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)65.94K

Market Cap

¥12.63B

Enterprise Value¥10.85B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)7.1

Beta0.36

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)10.05

Shares Outstanding34,838,326

10 Day Avg. Volume55,010

30 Day Avg. Volume65,936

Financial Highlights & Ratios

PEG Ratio-4.19

Price to Book (P/B)0.95

Price to Sales (P/S)1.41

P/FCF Ratio-10.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA robust equity position and low leverage provide durable financial stability, enabling the company to fund R&D, maintain distribution, and withstand sector cyclicality. Low debt reduces default risk and preserves strategic optionality for 2–6 month horizon investments.

Recent Revenue ImprovementA recent uptick in revenue after prior fluctuations indicates renewed demand or better execution. Sustained top-line growth supports scale economies, can lift margins over time, and provides a foundation for reinvestment in marketing and product development.

Diversified Sales Channels And BrandMultiple revenue streams (consumer OTC, ethical prescription, healthcare products) and the established Wakamoto brand create durable revenue diversification. Channel variety reduces single-market exposure and supports steadier cash flows across market cycles.

Bears Say

Negative Operating Cash FlowPersistent negative operating and free cash flow impairs the firm’s ability to self-fund operations, capex, or payouts. Over months this forces reliance on external financing, increases liquidity risk, and constrains strategic investments and margin recovery plans.

Declining Profitability / ROEDiminishing ROE from falling net income signals weakening returns on invested capital. If sustained, this reduces internal funding capacity, undermines investor confidence, and limits resources available to defend market share or invest in product pipelines.

Operating Inefficiency (negative EBIT)A negative EBIT margin shows core operations do not yet cover operating costs before financing. Persistent operating losses hinder profit generation, reduce ability to build cash reserves, and make long-term margin recovery and competitive investment more difficult.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥270.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥12.63B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 18, 2026 which is in 52 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥10.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥10.05.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥10.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.